ClinicalTrials.gg
CompletedNCT03096795Updated Oct 5, 2020

Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants

A Phase 1 interventional study of MEDI3506 and Placebo in Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease and Part III (J-SD) - Healthy Japanese Participants, sponsored by MedImmune LLC. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-05.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
118th of 194
88 · median 137
Started
2017
with 13 others
Phase 1
42 of 284
none open now
Registered
199th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 118th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2017, is one of 42 in phase 1, and was the 199th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.

Read the detailed description

This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506 administered by either subcutaneous (SC) or intravenous (IV) routes.

Part I: Single Ascending Doses in Healthy Participants with a History of Mild Atopy

Part II: Multiple Ascending Doses in Participants with Global Initiative for Chronic Obstructive Lung Disease (GOLD) I-II Chronic Obstructive Pulmonary Disease (COPD)

Part III: Single Dose in Healthy Japanese Participants

03

Conditions studied

  • Part I (SAD) - Healthy Participants
  • Part II (MAD) - Chronic Obstructive Pulmonary Disease
  • Part III (J-SD) - Healthy Japanese Participants

Keywords

  • MEDI3506
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Immunogenicity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria Part 1

  1. Healthy volunteers aged 18 through 55 years at the time of consent.
  2. Non-smokers, healthy current smokers, and ex-smokers are permitted.
  3. Pre-bronchodilator (FEV1) >= 80% predicted (using the Global Lung Initiative [GLI] predicted values) at screening.
  4. (BMI) of 19.0 through 32.0 kg/m\^2 at screening.
  5. Current history of mild atopy.

Inclusion Criteria Part 2

  1. Aged 40 through 80 years at the time of screening.
  2. BMI of 19.0 through 35.0 kg/m\^2 at screening.
  3. Participants must be current on pneumococcus and annual influenza vaccines.
  4. Documented history of with a post-bronchodilator FEV1/force vital capacity (FVC) \<0.70 and a post-bronchodilator FEV1 ≥50% predicted at screening.
  5. Clinically stable and free from an acute exacerbation of COPD for 8 weeks prior to Day 1.
  6. Current or ex-smoker with a tobacco history of ≥10 pack-years.

Inclusion Criteria Part 3

  1. Japanese participants must have been born in Japan, have both parents and grandparents of Japanese origin, and not have lived outside of Japan for more than 5 years.
  2. Healthy participants aged 20 through 55 years at the time of consent.
  3. Non-smokers, healthy current smokers, and ex-smokers are permitted.
  4. BMI of 18.0 through 32.0 kg/m\^2 at screening.

Exclusion Criteria Part 1

  1. Concurrent enrollment in another clinical study involving a study treatment.
  2. Received administration of study drug or participated in a device trial within 3 months, prior to screening (Visit 1).
  3. Participant is a participating investigator, sub-investigator, study coordinator or employee of the participating site, or is a first-degree relative of the aforementioned.
  4. Any active medical or psychiatric condition or other reason which, in the opinion of the investigator or medical monitor, may compromise the safety of the participant in the study or interfere with evaluation of the product or reduce the participant's ability to participate in the study.
  5. Any abnormal findings on physical examination of the cardiovascular system including (ECG) and vital signs at screening or randomization.
  6. Abnormal vital signs, after 10 minutes supine rest.

Exclusion Criteria Part 2

  1. Concurrent enrolment in another clinical study involving investigational treatment.
  2. Received administration of study drug or participated in a device trial within 3 months, prior to screening (Visit 1).
  3. Participant is a participating investigator, sub-investigator, study coordinator, or employee of the participating site, or is a first-degree relative of the aforementioned.
  4. Any active medical or psychiatric condition or other reason that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of participant's safety or study results. This includes, but is not limited to:

    • Uncontrolled diabetes
    • Hypertension during the screening period
    • Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure
    • Clinically significant Aortic stenosis
    • Pulmonary Arterial Hypertension

Exclusion Criteria Part 3

  1. Concurrent enrolment in another clinical study involving study treatment.
  2. Received administration of study drug or participated in a device trial within 3 months, prior to screening (Visit 1).
  3. Any active medical or psychiatric condition or other reason which, in the opinion of the investigator or medical monitor, may compromise the safety of the participant in the study or interfere with evaluation of the study product or reduce the participant's ability to participate in the study.
  4. Any clinically relevant abnormal findings on physical examination of the cardiovascular system including ECG and vital signs at screening, and Day 1(pre-dose).
  5. Any other clinically relevant abnormal findings on physical examination or laboratory testing including hematology, coagulation, clinical chemistry or urinalysis at screening or randomisation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Placebo comparator
    Part 1: Placebo

    Healthy participants with a history of mild atopy and proven sensitivity to house dust mite (HDM) will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously.

    Drug: MEDI3506 · Drug: Placebo

  • Experimental
    Part 1: MEDI3506 SC Dose 1

    Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 subcutaneously.

    Drug: MEDI3506

  • Experimental
    Part 1: MEDI3506 SC Dose 2

    Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 2 subcutaneously.

    Drug: MEDI3506

  • Experimental
    Part 1: MEDI3506 SC Dose 3

    Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 3 subcutaneously.

    Drug: MEDI3506

  • Experimental
    Part 1: MEDI3506 SC Dose 4

    Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 4 subcutaneously.

    Drug: MEDI3506

  • Experimental
    Part 1: MEDI3506 SC Dose 5

    Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 5 subcutaneously.

    Drug: MEDI3506

  • Experimental
    Part 1: MEDI3506 SC Dose 6

    Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 subcutaneously.

    Drug: MEDI3506

  • Experimental
    Part 1: MEDI3506 IV Dose 6

    Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 intravenously.

    Drug: MEDI3506

  • Placebo comparator
    Part 2: Placebo

    Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).

    Drug: MEDI3506 · Drug: Placebo

  • Experimental
    Part 2: MEDI3506 SC Dose 4

    Participants with COPD will receive 3 administration of MEDI3506 Dose 4 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).

    Drug: MEDI3506

  • Experimental
    Part 2: MEDI3506 SC Dose 5

    Participants with COPD will receive 3 administration of MEDI3506 Dose 5 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).

    Drug: MEDI3506

  • Experimental
    Part 2: MEDI3506 SC Dose 6

    Participants with COPD will receive 3 administration of MEDI3506 Dose 6 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).

    Drug: MEDI3506

  • Placebo comparator
    Part 3: Placebo

    Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously.

    Drug: MEDI3506 · Drug: Placebo

  • Experimental
    Part 3: MEDI3506 IV Dose 6

    Healthy Japanese participants will receive a single MEDI3506 Dose 6 intravenously.

    Drug: MEDI3506

Interventions

  • Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.

  • DrugPlacebo

    Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (TEAESI) in Part 1, Part 2, and Part 3

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. An adverse event of special interest (AESI) was defined as any serious or nonserious event of scientific and medical interest specific to understand the study drug.

    Time frame: From Day 1 through Day 169

  2. Number of Participants With Grade 2 or More Toxicity Grades Reported in Laboratory Parameters at Day 169 for Part 1, Part 2, and Part 3

    Number of participants with Grade 2 or more toxicity grades reported in laboratory parameters are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of hematology and serum chemistry.

    Time frame: Day 169

  3. Changes From Baseline in Blood Pressure at Day 169 in Part 1, Part 2, and Part 3

    Change from baseline in blood pressure at Day 169 in Part 1, Part 2, and Part 3 are reported.

    Time frame: Day 169

  4. Changes From Baseline in Pulse Rate at Day 169 in Part 1, Part 2, and Part 3

    Change from baseline in pulse rate at Day 169 in Part 1, Part 2, and Part 3 is reported.

    Time frame: Baseline (Day 1) and Day 169

  5. Changes From Baseline in Respiratory Rate at Day 169 in Part 1, Part 2, and Part 3

    Change from baseline in respiratory rate at Day 169 in Part 1, Part 2, and Part 3 are reported.

    Time frame: Baseline (Day 1) and Day 169

  6. Changes From Baseline in Body Temperature Rate at Day 169 in Part 1, Part 2, and Part 3

    Change from baseline in body temperature at Day 169 in Part 1, Part 2, and Part 3 are reported.

    Time frame: Baseline (Day 1) and Day 169

  7. Number of Participants With Change From Baseline in QTcF in Part 1, Part 2, and Part 3

    Number of participants with change from basleine in QTcF in Part 1, Part 2, and Part 3 are reported. The change from baseline in QTcF at Day 169 data are reported in 3 categories as: \<= 30 msec, \> 30 to \<= 60 msec, and \> 60 msec.

    Time frame: Baseline (Day 1) and Day 169

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of MEDI3506 After Single Dose for Part 1 and Part 3

    The Cmax of MEDI3506 after single dose for Part 1 and Part 3 are reported.

    Time frame: Day 1 (predose for all arms; except predose and end of infusion for MEDI3506 IV Dose 6 arms), Day 2, Day 3, Day 4, Day 5, Day 8, Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, and Day 169

  2. Time to Maximum Concentration (Tmax) of MEDI3506 After Single Dose for Part 1 and Part 3

    The Tmax of MEDI3506 after single dose for Part 1 and Part 3 is reported.

    Time frame: Day 1 (predose for all arms; except predose and end of infusion for MEDI3506 IV Dose 6 arms), Day 2, Day 3, Day 4, Day 5, Day 8, Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, and Day 169

  3. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3506 After Single Dose for Part 1 and Part 3

    The AUC0-inf of MEDI3506 after single dose for Part 1 and Part 3 are reported.

    Time frame: Day 1 (predose for all arms; except predose and end of infusion for MEDI3506 IV Dose 6 arms), Day 2, Day 3, Day 4, Day 5, Day 8, Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, and Day 169

  4. Terminal Elimination Half-life (t1/2) of MEDI3506 After Single Dose for Part 1 and Part 3

    The t1/2 of MEDI3506 after single dose for Part 1 and Part 3 are reported.

    Time frame: Day 1 (predose for all arms; except predose and end of infusion for MEDI3506 IV Dose 6 arms), Day 2, Day 3, Day 4, Day 5, Day 8, Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, and Day 169

  5. Apparent Clearance (CL/F) of MEDI3506 From Body After Single Dose for Part 1 and Part 3

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Total clearance from the body (CL) from Part 1 and Part 3 after intravenous administration or apparent systemic clearance (CL/F) after subcutaneous administration in Part 1 of the study are reported.

    Time frame: Day 1 (predose for all arms; except predose and end of infusion for MEDI3506 IV Dose 6 arms), Day 2, Day 3, Day 4, Day 5, Day 8, Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, and Day 169

  6. Trough Serum Concentration (Ctrough) of MEDI3506 After 1st Dose in Part 2

    Lowest serum concentration of MEDI3506 observed within the dosing interval after 1st dose in Part 2 is reported.

    Time frame: Day 1 (predose), Day 3, Day 8, Day 15 (predose)

  7. Trough Serum Concentration (Ctrough) of MEDI3506 After 3rd Dose in Part 2

    Lowest serum concentration of MEDI3506 observed within the dosing interval after 3rd dose in Part 2 is reported.

    Time frame: Day 29 (predose), Day 36, and Day 43

  8. Terminal Elimination Half-life (t1/2) of MEDI3506 in Part 2

    The t1/2 of MEDI3506 after 3rd dose in Part 2 is reported.

    Time frame: Day 36, Day 43, Day 57, Day 85, Day 113, Day 141, and Day 169

  9. Number of Participants With Positive Anti-drug Antibodies (ADA) to MEDI3506 treatment in Part 1, Part 2, and Part 3

    Number of participants with positive ADA to MEDI3506 treatment after single administration of MEDI3506 (Part 1 and Part 3) and after multiple dose administration of MEDI3506 (Part 2) at any time point during the study are reported.

    Time frame: Part 1 and Part 3: Day 1 (predose), Day 29, Day 57, Day 85, Day 113, Day 141, and Day 169; Part 2: Day 1 (predose), Day 29, Day 85, and Day 169

07

Study locations

2 sites
  • Research Site
    London, HA1 3UJ, United Kingdom
  • Research Site
    Manchester, M23 9QZ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Sep 2019, 28 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 28 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2017
First posted
Mar 30, 2017
StartActual
May 15, 2017
Primary completionActual
Sep 30, 2019
CompletionActual
Sep 30, 2019
Last update
Oct 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03096795
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Mar 30, 2017
Start date
May 15, 2017
Primary completion
Sep 30, 2019
Completion
Sep 30, 2019
Last update
Oct 5, 2020

Study contacts

Muna Albayaty, MBChB, FFPM. MSc
principal investigator · Parexel
David Singh, MD
principal investigator · Medicines Evaluation Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tozorakimab

Start the discussion